Pfizer Inc (NYSE: PFE) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 4% decline in Q3 revenues to $12.1 billion, which fell short of the Wall Street consensus. Earnings of $0.72 per share were, meanwhile a cent higher than what analysts had anticipated.
PFE shares fell 0.2% immediately following the announcement. The stock has fallen 2.5% since the beginning of this year.
CFO Frank D’Amelio said, “In the first nine months of the year, our Biopharma business grew 7% operationally, despite a COVID-19-related negative impact of approximately 2%, driven by the strong performance of many of our key brands. This performance adds to our confidence in our ability to achieve our expectation of at least a 6% compound annual revenue growth rate through 2025 for New Pfizer.”
Meanwhile, shares of Merck & Co., Inc. (NYSE: MRK) gained 1.65% after reporting Q3 earnings and sales that topped street targets.
Prior performance
Most Popular
V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results
Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew
Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results
Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter
McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings
Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings
